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incidence and epidemiology
Breast cancer is the most common cancer in women in
almost all countries, including developing countries. In 2008,
1 380 000 new cases and 458 000 breast cancer deaths were
noted in the world and 332 000 new cases/89 000 deaths in the
European Union. The age-standardized incidence in Europe
was 62.8/100 000 and the mortality—16.7/100 000 women/
year. Since 1990, the incidence rate has increased 1.5%
annually. Owing to advances both in early detection and in
adjuvant systemic therapy, mortality rates from breast cancer
have been decreasing steadily in most Western countries since
the early 1990s. However, it is still the leading cause of cancer
death in women in both developing (269 000 deaths, 12.7% of
total) and developed (189 000 deaths, 15.5% of total) regions.
Approximately 5% to 10% of breast cancers are metastatic at
diagnosis; of these, approximately one-ﬁfth will survive 5 years.
Depending on prognostic factors, up to 30% of node-negative
and up to 70% of node-positive breast cancers will relapse. The
prevalence of metastatic disease is high because many women
live with this disease for several years; there is however, a major
lack of accurate data on this prevalence in the great majority of
countries since most cancer registries do not capture relapses.
As there are signiﬁcant variations in outcomes of early breast
cancer among different regions, the burden of metastatic breast
cancer (MBC) may differ from that of early disease.
diagnosis and pathology
Clinical suspicion must be conﬁrmed by imaging. A minimal
staging work-up should include a complete history and
physical examination, hematology and biochemistry tests,
imaging of chest, abdomen and bone; in certain situations,
information may be provided by functional imaging such as
PET–CT (positron emission tomography–computed
tomography scan), DCE-MRI (dynamic contrast-enhanced
magnetic resonance imaging) or MR-DWI (diffusion-weighted
magnetic resonance) (in particular, in case of equivocal results
of routine imaging or when these exams fail to detect the
location of the relapse, or when pathology from suspicious
lesion cannot be obtained).
Efforts should be made to obtain histopathological
conﬁrmation whenever technically feasible, particularly in the
situation of an isolated metastatic lesion. Biological markers
important for treatment decisions, such as steroid hormone
receptors (ER, PR) and HER-2 status should be re-evaluated, at
least once, in a metastatic lesion. Although there are no data to
support the choice of therapy in case of discordance in HR/HER-
2 status between primary and metastatic tumor, retrospective
data suggest inferior outcome in ‘discordant’ patients (possibly
due to inappropriate treatment, not adjusted for biomarker
changes). It seems appropriate to recommend that, if at any
given biopsy the receptors were positive, targeted therapy
(endocrine and/or anti-HER-2 therapy) should be provided.
There is no proven value of routine ‘screening’ tests for
metastatic disease in asymptomatic early breast cancer patients.
However, the available data are from a time when neither
biological therapy nor effective (in terms of local control) and
less invasive (in terms of quality of life and side-effects)
locoregional therapeutic techniques, such as radiosurgery for
central nervous system (CNS) metastases or radiofrequency
ablation for liver metastases, were available. In addition, new
detection techniques are now available, such as MRI, PET-
scan, PET–CT and others, that may allow the detection of very
early metastatic disease. Therefore, new studies are needed to
evaluate the role of early diagnosis of metastatic disease in the
current context.
The occurrence of locoregional recurrence is often associated
with distant spread and such patients should undergo full
staging procedures before undergoing local treatments.
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The value of multigene assays used for recurrence risk
assessment in early breast cancer has not been conﬁrmed in
advanced disease.
treatment: general statements
locoregional recurrence
Whenever possible, isolated locoregional recurrence should be
treated with a curative intent (Figure 1). If feasible, complete
excision of recurrent tumor is recommended. In patients
previously treated by breast-conserving surgery, a mastectomy
should be carried out [III, A]. In patients not previously
irradiated, full-dose radiotherapy to chest wall and regional
lymph node areas should be given [III, A]. In those previously
irradiated, re-irradiation to limited areas of the chest wall may
be applied, taking into consideration the duration of radiation-
free period, intensity of existing late radiation effects and the
risk of additional local–regional relapse [III, B]. Inoperable
patients can, if feasible, undergo radical radiotherapy to chest
wall and regional lymph node areas with boost to macroscopic
disease sites. However, in these patients, primary systemic
therapy to decrease the size of the tumor and render it
operable is preferred [III, B].
The value of ‘secondary’ or ‘pseudo-adjuvant’ systemic
treatment is not well proven. The role of chemotherapy in this
setting is a subject of ongoing randomized studies [II, B].
Factors such as tumor biology and aggressiveness, prior
adjuvant systemic therapy, patient co-morbidities and
preferences should all be taken into account when deciding
whether to propose ‘pseudo-adjuvant’ chemotherapy (expert
opinion). Although not well proven, ‘pseudo-adjuvant’
endocrine therapy is a reasonable option in view of its
expected beneﬁt and low toxicity [II, B]. ‘Pseudo-adjuvant’
trastuzumab therapy is also acceptable, particularly in cases
where adjuvant trastuzumab was not prescribed at the time of
initial diagnosis (expert opinion).
In patients not suitable for local treatment with curative
intent (e.g. inoperable, previously irradiated), systemic
therapies remain the mainstay of treatment. Their choice
depends on tumor biology, previous systemic treatments,
duration of disease-free interval, patient co-morbidities and
preferences.
metastatic disease
The management of MBC should involve all appropriate
specialties in a multi/interdisciplinary team (medical, radiation,
surgical and imaging oncologists, palliative care specialist,
psychosocial support), and patients should be offered
personalized appropriate psychosocial, supportive and
symptom-related interventions as a routine part of their care.
Table 2. Factors to consider in risk assessment and treatment decision-
making for MBC
Disease-related factors Patient-related factors
Disease-free interval Patient preferences
Previous therapies and response Biological age
Biological factors (hormonal
receptors, HER-2)
Menopausal status
Tumor burden (number and site of
metastases)
Co-morbidities and performance
status
Need for rapid disease/symptom
control
Socio-economic and psychological
factors
Therapies available in the patient’s
country
Table 1. Staging and assessment of prognosis
Complete history, including
menopausal status
co-morbidities (e.g. cardiac diseases, diabetes mellitus, thromboembolic
diseases, renal or liver disease)
detailed history of the primary tumor, its biology, management and status
at the last follow-up
history of recurrent/metastatic disease, including duration, previous sites of
involvement, previous treatments and their effect
current symptoms, performance status, socio-economic background and
preferences (Table 2)
Detailed physical examination
Blood and other laboratory tests: complete blood count, liver and renal
function tests, alkaline phosphatase, LDH, calcium and, if applicable,
speciﬁc tests required for particular treatments such as urinary protein.
The clinical value of tumor markers for diagnostic purposes has not
been proven. However, they may assist in evaluating response to
treatment (i.e. monitoring), particularly in patients with non-measurable
disease
Assessment of visceral disease
Chest: preferably CT; chest X-ray has low sensitivity and should be
replaced by chest CT whenever possible
Abdomen: ultrasound, CT (preferably) or MRI
Bone scan, with conﬁrmation of lesions and further work-up (i.e. fracture
risk, etc.) if needed by X-ray/CT/MRI
CT and/or MRI of the CNS should be symptom-driven; the value of
‘screening’ for asymptomatic brain metastases, even in breast cancer
subtypes with higher risk of developing CNS involvement (HER-2-
positive and triple-negative breast cancer), is not established and should
not be carried out routinely
All imaging should be carried out in a way that will allow for future
comparative assessment to evaluate the treatment effect
PET/PET–CT should not be used routinely as part of the initial work-up
but can be useful for identifying the site of relapse when traditional
imaging methods are equivocal or conﬂicting. It may also be helpful to
identify or conﬁrm isolated locoregional relapse or isolated metastatic
lesions, a situation where patients may beneﬁt from a more aggressive
multidisciplinary approach
Estrogen, progesterone and HER-2 receptors of the metastatic lesion should
be obtained at least once in the evolution of the disease, if technically
possible, and particularly if not available from the primary tumor
Cardiac assessments, in particular in HER-2-positive patients and those
considered for anthracycline-based chemotherapy
Circulating tumor cells are still an experimental technique and should not
be used outside a clinical trial
In case of lesions inaccessible for biopsy, functional imaging such as PET–
CT, DCE-MRI or MR-DWI may be helpful to conﬁrm their malignant
character
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Specialist breast nurses can provide crucial support, as well as
coordination and continuity of care for patients with advanced
breast cancer and should be available to all patients. Countries
in which this nurse subspecialty does not yet exist, should
make all efforts to establish it.
There are only a few proven standards of care in MBC
management, therefore well-designed, independent, prospective
randomized trials are a priority. Participation in such clinical
trials should be offered to all eligible patients, whenever
available.
The vast majority of MBC is incurable and hence the main
treatment goal is palliation, with the aim of maintaining/
improving quality of life and possibly prolonging survival.
The realistic treatment goals should be discussed with the
patient and her/his caregivers from the beginning and the
patient should be encouraged to actively participate in all
decisions. Patient preferences should always be taken into
account.
Systemic treatment options for MBC are endocrine therapy,
chemotherapy, bone-directed agents (e.g. bisphosphonates,
denosumab) and targeted biological agents such as
trastuzumab and lapatinib [I, A].
The choice of therapy should be made after consideration of
factors listed in Table 2.
For the majority of patients, overall survival outcomes
from sequential use of single-cytotoxic drugs are equivalent
to combination chemotherapy. The choice between these
options should primarily take into account the need for a
rapid and signiﬁcant response, as well as quality of life. In
patients without directly life-threatening or severely
symptomatic disease, single-agent chemotherapy is the
preferred option.
Duration of each regimen and number of regimens should
be tailored to each individual patient.
In HR-positive and HER-2-negative disease, endocrine
therapy is the treatment of ﬁrst choice independent of
metastatic site, unless rapid response is needed. Limited
visceral metastases are not a contraindication for endocrine
therapy. Chemo and endocrine therapy should not be given
concomitantly. Given its low toxicity, endocrine maintenance
should be considered.
In patients with HER2, overexpressing/ampliﬁed early
incorporation of targeted anti-HER-2 agents is highly
recommended unless speciﬁc contra-indications exist.
The most common indications for palliative radiotherapy
include:
Bone metastases which are painful or carry a risk of fracture
and/or neurological complications (radiotherapy options
include ‘limited ﬁeld’ external beam irradiation, hemi-body
irradiation and application of radioactive ‘bone-seeking’
isotopes);
Brain metastases—patients with extensive cerebral
involvement usually require whole-brain radiotherapy
(WBRT); in those with single or few metastatic foci,
stereotactic radiosurgery can be used as an alternative to
surgical resection, with improvement in local control and
less side-effects than WBRT; addition of WBRT to surgery
or stereotactic radiosurgery decreases the number of
intracranial relapses but increases substantially side-effects,
mainly cognitive, and should be discussed with the patient;
Painful or fungating soft-tissue masses.
For limited metastatic presentations, surgery or radical
radiotherapy may be considered. Systemic tumor control should
be the prerequisite for tumor-reduction local therapy in
metastatic disease. Although no randomized data exist, a bulk of
retrospective data suggest a signiﬁcant survival beneﬁt from the
removal of the primary tumor (with clear margins) in patients
Figure 1 Management of locoregional recurrence.
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with primary metastatic disease. Prospective randomized trials
addressing this question are currently ongoing.
Palliative surgery may be utilized to prevent or stabilize
pathological fractures, remove fungating soft-tissue masses or
relieve compression leading to neurological deﬁcits.
Bisphosphonates or RANK-ligand antibody denosumab
should be used for the treatment of clinically evident bone
metastases (to palliate symptoms and decrease risk of bone
events) [I, A]. Bone-directed therapy should be started
following a diagnosis of bone metastases. Although the optimal
duration of these treatments is unknown and the beneﬁt of
duration beyond 2 years has not been demonstrated in clinical
trials, an ongoing risk of skeletal events persists, especially at
times of disease progression and thus long-term treatment
seems appropriate. The impact of bisphosphonate or
denosumab-associated side-effects (including osteonecrosis of
the jaw and nephrotoxicity) is minor, and for the vast majority
of patients the beneﬁt of treatment outweighs the risks. The
choice between bisphosphonates and denosumab depends on
drug availability, presence of possible contraindications (renal
insufﬁciency) and patient preferences.
A multi-disciplinary discussion including pain control
experts, radiation oncologists, medical oncologists, surgeons
specialized in bone treatment and radiologists with expertise
in vertebroplasty/kyphoplasty is crucial to determine the best
therapeutic approach for the individual patient. A pathway
for rapid (within 24 h) assessment of patients with spinal
cord compression should be available with access to
specialist spinal surgeons for decompression and stabilization
of compressing or unstable spinal lesions when clinically
appropriate.
Malignancy-related hypercalcemia should be treated with
bisphosphonates and intravenous ﬂuids.
The choice of drugs for MBC, their timing, optimal
duration, methods of administration and side-effects should be
considered individually, taking into account patient
preferences, expected treatment acceptance and adherence.
Availability and reimbursement issues must also be taken into
account.
treatment-speciﬁc breast cancer
subtypes
luminal breast cancer (hormone receptor-positive,
irrespective of HER-2 status) (Figure 2)
Endocrine therapy is the preferred option except if clinically
aggressive disease mandates a quicker response or if there are
doubts regarding endocrine responsiveness of the tumor.
Available endocrine agents are listed in Table 3.
The choice of endocrine agent should be based on
menopausal status, co-morbidities, agents received in the
adjuvant setting and the drug safety proﬁle.
Apart from combination of ovarian suppression with
tamoxifen [or aromatase inhibitors (AIs)] in premenopausal
patients, there is no rationale for the use of combination
endocrine therapies.
Figure 2 First-line systemic therapy for advanced breast cancer.
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The value of maintenance endocrine treatment after
chemotherapy has not been conﬁrmed by controlled clinical
studies, but—given its low toxicity and potential beneﬁts—is a
reasonable approach (expert opinion).
Concomitant chemo-endocrine therapy should not be used
outside clinical trials.
In case of ER-positive/HER-2-positive breast cancer with no
indication for chemotherapy, endocrine therapies should be
combined with anti-HER-2 therapies (trastuzumab, lapatinib)
since they lead to a signiﬁcant improvement in progression free
survival (in this case equivalent to ‘time without
chemotherapy’), although no beneﬁt in overall survival,
compared with endocrine therapy alone.
premenopausal patients
If no prior adjuvant tamoxifen or if discontinued for >12
months, tamoxifen with ovarian ablation (luteinizing
hormone-releasing hormone analogue, surgery or ovarian
irradiation) is the preferred option [I, B]. Further treatment
lines (in patients with ovarian ablation/suppression) do not
differ from those used in postmenopausal population (as
described below).
postmenopausal patients
If not used in the adjuvant setting or if discontinued for >12
months, AIs (anastrozole, letrozole, exemestane) are the
preferred option since they have consistently shown superior
results to tamoxifen as ﬁrst-line therapy in terms of response
rate, time to progression and, for letrozole, in 2-year overall
survival [II, A]. Preferably, a nonsteroidal AI should be used
after progression on a steroidal AI and vice versa. The risk of
accelerated bone loss needs to be considered and calcium and
vitamin D supplements are recommended.
Tamoxifen remains an acceptable ﬁrst-line therapy.
Although deﬁnitive data are still needed, it seems reasonable to
advise patients under tamoxifen to avoid, whenever possible,
the use of drugs modulating the activity of CYP2D6, such as
some selective serotonin reuptake inhibitor antidepressants (e.
g. paroxetine, ﬂuoxetine). Fulvestrant at the dose of 500 mg
every 4 weeks has demonstrated superiority compared with
anastrozole in the ﬁrst-line setting [II, A].
Second and further lines of endocrine therapy may include
(if not previously used) tamoxifen, steroidal or nonsteroidal
AIs, fulvestrant, progestins (e.g. megestrol acetate) and
androgens. No deﬁnitive recommendation can be given for a
speciﬁc endocrine treatment cascade, and particularly, the best
option after progression on ﬁrst-line AI therapy is currently
unknown.
Recent evidence suggests that the addition of the m-TOR
inhibitor everolimus to either a steroidal AI or tamoxifen may
improve outcome, compared with endocrine therapy alone, in
patients progressing on/after AI therapy but additional
research is needed to clearly identify those patients who may
beneﬁt from this approach. Additionally, everolimus is not yet
approved by the European Medicines Agency (EMA) or
United States Food & Drug Administration (FDA) although it
has been approved in some countries.
Patients with clear evidence of endocrine resistance should
be offered chemotherapy. No overall recommendation can be
made regarding the number of lines of endocrine therapy
before switching to chemotherapy. Factors that need to be
taken into account in this treatment decision include response
to previous endocrine therapies and its duration, presence of
symptoms and/or rapidly progressive or life-threatening
disease, patient preference and performance status, as well as
the estimated tolerability of chemotherapy (Figure 3).
‘triple-negative’ breast cancer
(hormonereceptor-negative and
HER-2-non-overexpressed/non-ampliﬁed)
Cytotoxic chemotherapy remains the mainstay of treatment in
this group. Available agents/regimens are listed in Table 4.
The selection of the best agent/regimen should be
individualized and should take into account the factors listed
in Table 2. Taxane-based regimens are the only standard of
care in ﬁrst-line therapy in patients progressing after adjuvant
anthracycline-based non-taxane-containing chemotherapy
regimens [I, A].
Because of frequent visceral involvement, aggressive course
and risk of rapid patient deterioration, combination
Table 3. Available endocrine therapies for MBC
Class of agent
Selective estrogen receptor modulators Tamoxifen; toremifene
Estrogen receptor down-regulator Fulvestrant
Luteinizing hormone-releasing hormone
analogues
Goserelin, leuprorelin,
triptorelin
Third-generation aromatase inhibitors
Non-steroidal Anastrozole, letrozole
Steroidal Exemestane
Progestins Medroxyprogesterone acetate;
megestrol acetate
Anabolic steroids Nandrolone decanoat
Estrogens Estrogens
Figure 3 Management of endocrine-responsive advanced breast cancer.
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chemotherapy is more often required. Triple-negative biology
on its own, however, is not a sufﬁcient reason to give
combination chemotherapy. There is no standard approach for
patients requiring second- or further-line chemotherapy
treatment.
Duration of each regimen and number of regimens should
be tailored to each individual patient. Continuing
chemotherapy beyond third-line may be justiﬁed in patients
with good performance status and response to previous
chemotherapy.
High-dose chemotherapy with stem cell support should not
be administered.
HER-2-positive (overexpressed/ampliﬁed) breast
cancer
Anti-HER-2 therapy (i.e. trastuzumab, lapatinib) in
combination with chemotherapy, endocrine therapy or alone
should be offered early to all HER-2-positive MBC patients [I,
A] who do not have contra-indications for these therapies.
Addition of pertuzumab to ﬁrst-line chemotherapy–
trastuzumab combination was associated with improved
response rate, progression-free survival (PFS) and a trend
toward improved overall survival in one randomized phase 3
trial. The patient population of this trial cannot, however, be
considered representative of the majority of ﬁrst-line ABC
patients since patients had received little adjuvant therapies
(90% did not receive adjuvant trastuzumab and ∼50% did not
receive adjuvant anthracycline/taxane-based chemotherapy).
The added value of this approach, its cost-effectiveness and
predictive biomarkers of response should be further evaluated.
Pertuzumab has recently been approved by the FDA and a
decision is awaited by the EMA.
Cytotoxic-antibody conjugate T-DM1 has demonstrated
superior efﬁcacy regarding PFS and a more favorable toxicity
proﬁle, when compared with the ﬁrst-line docetaxel–
trastuzumab combination. T-DM1 is not yet approved by the
EMA or FDA.
Continuing trastuzumab, in combination with a different
chemotherapy regimen, after the ﬁrst disease progression is
superior to chemotherapy alone [II, B]. The beneﬁt of
continuing anti-HER-2 therapy beyond ﬁrst progression is
based on less data but available evidence suggests to continue
anti-HER-2 therapy for as long as possible.
Lapatinib in combination with capecitabine, compared with
capecitabine alone, increases time to progression in patients
progressing after/on trastuzumab, anthracyclines or taxanes.
The question of continuing trastuzumab or changing to
lapatinib at the time of ﬁrst progression remains open.
The combination of trastuzumab and lapatinib seems to be
superior in terms of overall survival to lapatinib monotherapy
in patients progressing after/on anthracyclines, taxanes or
trastuzumab (not yet approved).
The addition of anti-HER-2 agents (trastuzumab or
lapatinib) to endocrine therapy allows for prolongation of PFS
and may be a viable option for some patients with ER/PR-
positive and HER-2-positive tumors, in particular in those not
considered for cytotoxic chemotherapy. In countries where
anti-HER-2 treatment is reimbursed only with a single therapy
treatment line, priority should be given to an anti-HER-
2 + chemotherapy combination, as it may enable a more rapid
and potentially more durable response (expert opinion).
other biological agents
• Bevacizumab, an anti-angiogenic agent, originally approved
by the FDA and the EMA for ﬁrst-line treatment of MBC,
failed to consistently demonstrate clinically relevant
improvement in PFS and has not improved overall survival.
For this reason and because of an unfavorable efﬁcacy–safety
proﬁle, the FDA revoked its conditional approval in 2011. In
Europe, bevacizumab remains approved, only as ﬁrst-line
therapy in combination with paclitaxel or capecitabine. It
may thus be considered in carefully selected patients with
limited treatment options, requiring a well thought out
balance between side-effects, beneﬁts and costs.
response evaluation
Response evaluation is routinely recommended every 2 to 4
months of endocrine therapy and every two or four cycles of
chemotherapy by clinical examination, evaluation of
symptoms, blood tests (including tumor markers if initially
elevated) and repeating the initially abnormal radiological
examinations with comparative measurements. The main aim
Table 4. Available chemotherapy agents/regimens for MBC
Anthracycline-containing
Doxorubicin or epirubicin monotherapy (weekly or tri-weekly)
Doxorubicin/cyclophosphamide or epirubicin/cyclophosphamide
Liposomal doxorubicin ± cyclophosphamide
Fluorouracil/doxorubicin/cyclophosphamide or ﬂuorouracil/epirubicin/
cyclophosphamide
Taxane-containing
Paclitaxel monotherapy weekly
Docetaxel monotherapy tri-weekly or weekly
Abraxane (nab-paclitaxel)
Anthracycline (doxorubicin or epirubicin)/taxane (paclitaxel or
docetaxel)
Docetaxel/capecitabine
Paclitaxel/gemcitabine
Paclitaxel/vinorelbine
Paclitaxel/carboplatin
New cytotoxic agents
Eribulin
Ixabepilone (not approved by EMA)
Non-anthracycline-containing
Cyclophosphamide/methotrexate/ﬂuorouracil (CMF)
Platinum-based combinations (e.g. cisplatinum + 5-ﬂuorouracil;
carboplatin + gemcitabine)
Capecitabine
Vinorelbine
Capecitabine + vinorelbine
Vinorelbine ± gemcitabine
Oral cyclophosphamide with or without methotrexate (metronomic
chemotherapy)
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of these assessments is to exclude progressive disease, in
particular in patients for whom further treatment options exist
or those who experience signiﬁcant toxic effects from their
treatment. The interval between assessments should be tailored
to the clinical needs of the patient and to the aggressiveness of
the disease and may be prolonged in case of indolent disease
and long-lasting responses. In case of clinical suspicion of
progressive disease, appropriate tests (imaging and laboratory)
should be carried out irrespective of scheduled examinations, if
necessary including areas not imaged in previous tests.
Bone scans should be used with caution and only if other
imaging tests are unavailable to solely assess response in bone
due to the risk of a ﬂare response being confused with
progression.
Serum tumor markers (such as CA 15-3 and/or CEA), if
initially elevated, may be helpful in monitoring response,
particularly in the case of non-measurable disease. However, a
change in tumor markers alone should not be used as the only
determinant for treatment decisions. Additionally, it is not
uncommon for a phenomenon of ﬂare of tumor markers to
occur in the ﬁrst 6 weeks of an efﬁcacious therapy and this
must be taken into account when interpreting serial values.
The role of PET/PET–CT in response assessment is still
under investigation but it may be used to determine disease
progression.
Maintenance of a good quality of life is paramount and can
best be achieved with prompt amelioration of symptoms and
side-effects of treatment. Psychometrically sound, well-
validated questionnaires are available to measure patient
reported outcomes. Efforts should be made to use them
regularly to help assess the impact of treatment and to monitor
symptoms that need prompt supportive intervention.
follow-up
Follow-up after curative treatment of local–regional recurrence
should be carried out as for primary breast cancer.
Patients with MBC must be seen frequently enough to
provide best possible palliation of symptoms and maintain
quality of life, which generally means every 2–4 months if on
endocrine therapy and every one or two cycles of
chemotherapy (with toxic effects and blood counts checked
before each chemotherapy cycle). If progression is suspected
(due to aggravation or appearance of new signs/symptoms and/
or signiﬁcant increase in tumor marker levels), response
evaluation should be done immediately.
There is no deﬁned optimal visit schedule for MBC patients
in disease remission with no active treatment; however, apart
from scheduled visits, these patients should be instructed to
contact their physician immediately in case of symptoms
suggestive of progressive disease or treatment complications.
Patients need good quality information and a care plan
outlining all aspects of treatment and care, clariﬁcation of the
purpose of different treatments, their side-effects and potential
impact on functional, emotional and social well-being.
Lifelong access to effective palliative care is mandatory.
note
Table 5 summarizes the recommendations for the management
of MBC. Levels of evidence [I–V] and grades of
recommendation [A–E] as used by the European Society for
Medical Oncology are given in square brackets. Statements
without grading were considered justiﬁed standard clinical
practice by the experts and the ESMO faculty.
Table 5. Summary of recommendations for management of metastatic
breast cancer
The management of metastatic breast cancer should involve all appropriate
specialties in a multi/interdisciplinary team
From the ﬁrst diagnosis of metastatic breast cancer, patients should be
offered personalized appropriate psychosocial, supportive and symptom-
related interventions as a routine part of their care
Following thorough assessment and conﬁrmation of metastatic breast
cancer, the realistic treatment goals must be speciﬁed and discussed.
Patients and caregivers (if patient agrees) should be invited to participate
in decision making
An aggressive multidisciplinary approach including local therapy may be
warranted in selected patients with limited metastatic disease
Minimal staging work-up for metastatic breast cancer includes a history
and physical examination, complete hematology and biochemistry,
imaging of chest, abdomen and bone. The clinical value of tumor
markers is not well established for diagnosis or follow-up; however, their
use for monitoring response to treatment, particularly in patients with
non-measurable disease, is useful
Treatment choice should take into account tumor biology and disease
burden, previous therapies and responses obtained, patient preferences,
performance status and co-morbidities, socio-economic, psychological
factors and therapies available in the patient’s country
Endocrine therapy is the preferred option for hormone receptor-positive
disease, unless rapid response is warranted or endocrine resistance is
suspected
HER-2-directed therapy should be offered early to all HER-2-positive
metastatic breast cancer patients, either as single agent, combined with
chemo- or with endocrine therapy. Patients progressing on an anti-HER-
2 therapy combined with a cytotoxic agent should be offered a second
line of anti-HER-2 therapy
Sequential mono-chemotherapy is the preferred option in metastatic breast
cancer in the absence of rapid clinical progression, life-threatening
visceral metastases or the need for rapid symptom and/or disease
control
There are only a few proven standards of care in metastatic breast cancer
management, and inclusion of patients in well-designed, independent,
prospective randomized trials must be a priority
In view of rising costs of metastatic breast cancer treatment, balanced
decisions should be made but patient well-being, length and quality of
life must always be the main decision factors
Validated patient reported outcome measures provide useful information
about symptom severity and the burden and the impact of these
symptoms on overall quality of life, and should be collected and
integrated with other clinical assessments, to form part of the treatment
decision making
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